RT Journal Article
SR Electronic
T1 SARS-CoV-2 viremia precedes an IL6 response in severe COVID-19 patients: results of a longitudinal prospective cohort
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.24.22269734
DO 10.1101/2022.01.24.22269734
A1 Emilia Roy-Vallejo
A1 Laura Cardeñoso
A1 Ana Triguero-Martínez
A1 Marta Chicot Llano
A1 Nelly Zurita
A1 Elena Ávalos
A1 Ana Barrios
A1 Julia Hernando
A1 Javier Ortiz
A1 Sebastián C. Rodríguez-García
A1 Marianela Ciudad Sañudo
A1 Celeste Marcos
A1 Elena García Castillo
A1 Leticia Fontán García-Rodrigo
A1 Begoña González
A1 Rosa Méndez
A1 Isabel Iturrate
A1 Ancor Sanz-García
A1 Almudena Villa
A1 Ana Sánchez Azofra
A1 Begoña Quicios
A1 David Arribas
A1 Jesús Álvarez Rodríguez
A1 Pablo Patiño
A1 Marina Trigueros
A1 Miren Uriarte
A1 Alexandra Martín-Ramírez
A1 Cristina Arévalo Román
A1 José María Galván-Román
A1 Rosario García-Vicuña
A1 Julio Ancochea
A1 Cecilia Muñoz Calleja
A1 Elena Fernández-Ruiz
A1 Rafael de la Cámara
A1 Carmen Suárez Fernández
A1 Isidoro González Álvaro
A1 Diego A. Rodríguez Serrano
A1 on behalf of the PREDINMUN- COVID Group
YR 2022
UL http://medrxiv.org/content/early/2022/01/24/2022.01.24.22269734.abstract
AB Background Interleukin 6 (IL6) levels and SARS-CoV-2 viremia have been correlated with COVID-19 severity. The association over time between them has not been assessed in a prospective cohort. Our aim was to evaluate the relationship between SARS-CoV-2 viremia and time evolution of IL6 levels in a COVID-19 prospective cohort.Methods Secondary analysis from a prospective cohort including COVID-19 hospitalized patients from Hospital Universitario La Princesa between November 2020 and January 2021. Serial plasma samples were collected from admission until discharge. Viral load was quantified by Real-Time Polymerase Chain Reaction and IL6 levels with an enzyme immunoassay. To represent the evolution over time of both variables we used the graphic command twoway of Stata.Results A total of 57 patients were recruited, with median age of 63 years (IQR [53-81]), 61.4% male and 68.4% caucasian. The peak of viremia appeared shortly after symptom onset in patients with persistent viremia (more than 1 sample with >1.3 log10 copies/ml) and also in those with at least one IL6>30 pg/ml, followed by a progressive increase in IL6 around 10 days later. Persistent viremia in the first week of hospitalization was associated with higher levels of IL6. Both IL6 and SARS-CoV-2 viral load were higher in males, with a quicker increase with age.Conclusions In those patients with worse outcomes, an early peak of SARS-CoV-2 viral load precedes an increase in IL6 levels. Monitoring SARS-CoV-2 viral load during the first week after symptom onset may be helpful to predict disease severity in COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded with grants: Fondos Supera COVID19 by Banco Santander and CRUE to CS, RG-V, CM and JA; RD16/0011/0012 and PI18/0371 to IGA, from Ministerio de Economia y Competitividad (Instituto de Salud Carlos III) and co-funded by European regional development fund (ERDF) A way to make Europe; and co-financed by the Community of Madrid through the Covid 2019 Aid. The work of ER-V has been funded by a Rio-Hortega grant CM19/00149 from the Ministerio de Economia y Competitividad (Instituto de Salud Carlos III) and co-funded by The European Regional Development Fund (ERDF) A way to make Europe. SR-G was funded by the Spanish Rheumatology Foundation (grants for physicians-researchers 2018-2021). None of these sponsors have had any role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Research Ethics Committee of Hospital Universitario La Princesa, Madrid, (register number 4267; 22-10-2020) and it was carried out following the ethical principles established in the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors